Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 15/20 | 0.49 |
| ▸ | CHUK | O15111 | 2/20 | 0.49 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 4/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106247 | 0.92 | IKBKB (0.49) | IKBKBCHUKEPHA3CDK8NTRK1 | |
| SCHEMBL5106374 | 0.89 | IKBKB (0.44) | IKBKBCHUKEPHA3CDK8NTRK1 | |
| SCHEMBL5116053 | 0.87 | IKBKB (0.44) | IKBKBCHUKEPHA3CDK8NTRK1 | |
| SCHEMBL5106391 | 0.87 | IKBKB (0.43) | IKBKBCHUKEPHA3CDK8NTRK1 | |
| SCHEMBL5110372 | 0.86 | IKBKB (0.47) | IKBKBCDK8 | |
| SCHEMBL5106407 | 0.86 | IKBKB (0.42) | IKBKBCHUKEPHA3CDK8NTRK1 | |
| SCHEMBL5117786 | 0.85 | CDK8 (0.42) | IKBKBCHUKEPHA3CDK8 | |
| SCHEMBL5114160 | 0.84 | CASP7 (0.42) | IKBKBCHUKEPHA3 | |
| SCHEMBL5115752 | 0.84 | CDK8 (0.43) | IKBKBCHUKEPHA3CDK8 | |
| SCHEMBL5116075 | 0.83 | IKBKB (0.40) | IKBKBCHUKEPHA3CDK8NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | claimed |
| EP-1651629-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050038104-A1 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | US | claimed |
| WO-2005012283-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1651629-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050038104-A1 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012283-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038104-A1 | Substitute benzothiophene compounds | TST, SULT1E1, LTC4S | IKBKB 338/4885CHUK 100/4885EPHA3 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.